Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs

Journal of Asthma and Allergy
2021.0

Abstract

Background: It has been demonstrated that ASHMI (antiasthma-simplified herbal medicine intervention) can improve airway function and reduce inflammation in human asthmatic patients with high safety and tolerability. In addition, ASHMI significantly suppresses Th2 cytokine production and increases Th1 cytokine production in treating asthma.; Objective: Allergic asthma is associated with dysregulation of cytokines. We focused on IL-5 and IL-10 as signature Th2 and Treg cytokines to characterize ASHMI immunomodu-latory components. Methods: The effects of ASHMI and individual herbal constituents on IL-5 and IL-10 production by PBMCs from asthmatic subjects were determined ex vivo. Sophora flavescens (SF)-F2, containing alkaloid compounds, effects on PBMC IL-10 and IL-5 production in the presence or absence of dexamethasone (Dex), and on DNA methylation levels at the foxp3 gene promoter were determined. Results: The ratio of anti-CD3/CD28 stimulated IL-10/IL-5 production by PBMCs from asthmatic subjects was significantly reduced compared to healthy subjects. In PBMCs from asthmatic subjects, ASHMI significantly reduced IL-5 production and increased IL-10 secretion in a dose-dependent manner (p < 0.05-0.01). SF-F2 was most effective in increasing IL-10, whereas SF-F4 (flavonoid compounds) was most effective in suppressing IL-5 production. Dex-treated PBMCs from asthma subjects showed a trend of increasing ratio of IL-10/IL-5 while demonstrating reduced levels in both IL-5 and IL-10 (p < 0.05). Co-culture with Dex and SF-F2 significantly prevented Dex suppression of IL-10, while retained Dex-suppression of IL-5 production, and increased IL-10/IL-5 ratio by Dex. Co-culture with SF- F2 and Dex significantly reduced DNA methylation levels at the foxp3 gene promoter at CpG-126. Conclusion: The SF alkaloid-rich fraction may be responsible for ASHMI induction of IL- 10 production by PBMCs and plays a synergistic effect with Dex for augmenting IL-10/IL-5 ratio. © 2022 Song et al.

Knowledge Graph

Similar Paper

Sophora flavescens Alkaloids and Corticosteroid Synergistically Augment IL-10/IL-5 Ratio with Foxp3-Gene-Epigenetic Modification in Asthma PBMCs
Journal of Asthma and Allergy 2021.0
Orally administered solasodine, a steroidal glycoalkaloid, suppresses ovalbumin-induced exaggerated Th2-immune response in rat model of bronchial asthma
Chemico-Biological Interactions 2022.0
Isorhynchophylline exerts anti-asthma effects in mice by inhibiting the proliferation of airway smooth muscle cells: The involvement of miR-200a-mediated FOXC1/NF-κB pathway
Biochemical and Biophysical Research Communications 2020.0
An Amide Alkaloid Isolated from Ephedra sinica Ameliorates OVA-Induced Allergic Asthma by Inhibiting Mast Cell Activation and Dendritic Cell Maturation
International Journal of Molecular Sciences 2022.0
Oxymatrine screened from Sophora flavescens by cell membrane immobilized chromatography relieves histamine-independent itch
Journal of Pharmacy and Pharmacology 2021.0
Characterization of alkaloids in Sophora flavescens Ait. by high-performance liquid chromatography–electrospray ionization tandem mass spectrometry
Journal of Pharmaceutical and Biomedical Analysis 2011.0
Sophoraflavanone G from Sophora alopecuroides inhibits lipopolysaccharide-induced inflammation in RAW264.7 cells by targeting PI3K/Akt, JAK/STAT and Nrf2/HO-1 pathways
International Immunopharmacology 2016.0
A New Compound, 1H,8H-Pyrano[3,4-C]Pyran-1,8-Dione, Suppresses Airway Epithelial Cell Inflammatory Responses in a Murine Model of Asthma
International Journal of Immunopathology and Pharmacology 2009.0
Alkaloids from the roots of Sophora flavescens and their anti-tumor activity
Fitoterapia 2023.0
Sophflarine A, a novel matrine-derived alkaloid from Sophora flavescens with therapeutic potential for non-small cell lung cancer through ROS-mediated pyroptosis and autophagy
Phytomedicine 2023.0